Vertex Pharmaceuticals (VRTX)
463.73  -0.39 (-0.08%)

Vertex Pharmaceuticals is a biotechnology company that focuses on discovering, developing, and commercializing innovative therapies to treat serious diseases. With an emphasis on cystic fibrosis, Vertex has pioneered groundbreaking treatments that significantly improve the lives of patients with this genetic disorder. In addition to its work in cystic fibrosis, the company is exploring potential therapies for other rare diseases, including pain management and beta-thalassemia. Vertex is dedicated to advancing scientific research and collaborating with the global medical community to bring new solutions to unmet medical needs.

SummaryNewsPress ReleasesChartHistorical
Previous Close464.12
Open462.33
Bid464.00
Ask466.70
Day's Range459.79 - 466.71
52 Week Range391.01 - 519.88
Volume1,097,111
Market Cap120.30B
PE Ratio (TTM)-233.03
EPS (TTM)-2.0
Dividend & YieldN/A (N/A)
1 Month Average Volume1,325,269

News & Press Releases

3 Unstoppable Stocks to Buy Right Nowfool.com
Via The Motley Fool · December 15, 2024
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Todaybenzinga.com
Via Benzinga · December 13, 2024
The Ultimate Biotech Stock to Buy With $500 Right Nowfool.com
Via The Motley Fool · December 12, 2024
10 Health Care Stocks With Whale Alerts In Today's Sessionbenzinga.com
Via Benzinga · December 10, 2024
2 No-Brainer Stocks to Buy Before the End of 2024fool.com
Via The Motley Fool · December 9, 2024
Vertex Has $5 Billion-Plus Opportunity In Pain And Kidney Disease Programs, Analyst Upgrades Stockbenzinga.com
Jefferies upgrades Vertex Pharmaceuticals to Buy, highlighting a promising pipeline and $5 billion-$7 billion growth potential from pain and kidney treatments.
Via Benzinga · December 9, 2024
Looking Into Vertex Pharmaceuticals's Recent Short Interestbenzinga.com
Via Benzinga · November 25, 2024
Got $500? 1 Biotech Stock to Buy and Hold Foreverfool.com
Via The Motley Fool · November 22, 2024
A Closer Look at Vertex Pharmaceuticals's Options Market Dynamicsbenzinga.com
Via Benzinga · November 18, 2024
A Glimpse Into The Expert Outlook On Vertex Pharmaceuticals Through 19 Analystsbenzinga.com
Via Benzinga · December 9, 2024
Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program Update
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced longer-term data for CASGEVY™ (exagamglogene autotemcel) from global clinical trials in people with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). CASGEVY is the first and only approved CRISPR/Cas9 gene-edited therapy.
3 No-Brainer Growth Stocks to Buy in Decemberfool.com
Via The Motley Fool · December 7, 2024
Should You Forget Pfizer and Buy These Unstoppable Stocks Instead?fool.com
Via The Motley Fool · December 5, 2024
FDA-Approved Sickle Cell Therapies From Bluebird Bio And Vertex Join Medicaid Innovation Programbenzinga.com
CMS launches an outcomes-based model to expand access to FDA-approved gene therapies for sickle cell disease, aiming to improve health outcomes and lower costs.
Via Benzinga · December 4, 2024
10 Health Care Stocks Whale Activity In Today's Sessionbenzinga.com
Via Benzinga · December 4, 2024
It’s Been A Tough Month For Healthcare Stockstalkmarkets.com
It’s been a very difficult month for the healthcare sector not only because of disappointing company news but also disruption caused by the election and future policy issues.
Via Talk Markets · December 2, 2024
Want $1 Million in Retirement? 3 Stocks to Buy Now and Hold for Decades.fool.com
Via The Motley Fool · November 28, 2024
Down 47% Since March, Is CRISPR Therapeutics Stock a Buy on the Dip?fool.com
Via The Motley Fool · November 24, 2024
3 Growth Stocks You Can Buy Right Now Without Any Hesitationfool.com
Via The Motley Fool · November 18, 2024
2 Top Biotech Stocks to Buy Now and Hold For 5 Years or Morefool.com
Via The Motley Fool · November 16, 2024
Prediction: This Biotech Stock Is Heading for a Once-in-a-Generation Opportunityfool.com
Regulators are reviewing what could become a multi-billion-dollar drug.
Via The Motley Fool · November 13, 2024
Biotech Stocks Are Rallying: What Is Your Playbook?talkmarkets.com
If you have been reading our posts you know that some of the big biotech winners have taken a hit after earnings : LLY, MRK and REGN. But ABBV, GILD, LLY, and VRTX remain among the top performers.
Via Talk Markets · November 11, 2024
Five S&P 500 Stocks, All Elite IBD Giants, Near Buy Pointsinvestors.com
Meta just forged a new base. All five stocks are on the IBD Leaderboard list.
Via Investor's Business Daily · November 9, 2024
2 Biotech Stocks You Can Buy Hand Over Fist This Monthfool.com
Both stocks have made significant breakthroughs.
Via The Motley Fool · November 8, 2024
Stock Market Surges To Highs On Trump Election; Fed Cuts Rates, Palantir Soars: Weekly Reviewinvestors.com
A Fed rate cut and a slew of big earnings reports filled out a busy week.
Via Investor's Business Daily · November 8, 2024